No­var­tis will change CRO re­la­tion­ships ‘over time’ as Sen­ate bill tar­get­ing Chi­nese com­pa­nies looms

No­var­tis is “ac­tive­ly” man­ag­ing its ex­ist­ing re­la­tion­ships with Chi­nese ser­vice providers to mit­i­gate risks if the Biose­cure Act pass­es.

CFO Har­ry Kirsch told me­dia on Tues­day morn­ing that No­var­tis cur­rent­ly has “a lit­tle bit of con­nec­tions” to Chi­nese providers such as CROs, al­though he did not spec­i­fy which ones.

“All of this is very man­age­able and is al­ready ac­tive­ly man­aged,” Kirsch said. “So, by the time this comes in­to ef­fect, we will have no ex­po­sure from our plan­ning. Very lim­it­ed at the mo­ment and that will be mit­i­gat­ed in a very rea­son­able time­frame.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER